PMOS and the Pill
The Pill and the Pamphlet
PMOS is four different conditions wearing one name. Which one you have changes what should be measured, what should be treated, and what you should refuse to accept.
You go in with a list.
Cycles that arrive when they feel like it. Skin that behaves like you are fifteen again. Hair in places you did not agree to. A tiredness that sleep does not touch. And a body that has stopped responding to the things that used to work on it.
You come out with a prescription for the pill and a suggestion about weight.
Maybe you get a name for it eventually. In one survey of 1385 women, a third of them spent more than two years looking for that name, and close to half saw three or more clinicians before anyone gave them one.[1]
Then comes the part that gets discussed less. Only 15.6% of those women were satisfied with the information they received when the diagnosis arrived.[1] So the wait ends, and the explaining does not start.
In May 2026 the condition got a new name, polyendocrine metabolic ovarian syndrome, after a global consensus process involving 56 organisations.[2] I wrote about that when it happened, and I stand by every word of it. But a name corrects the label on the file. It does not tell you what is happening inside you, or why the pill was offered, or what to ask for instead.
So this is the longer version. What PMOS is, why it takes years to find, and the specific thing about it that the standard consultation keeps getting wrong.
Four conditions, one name
Diagnosis rests on the Rotterdam criteria: you need two of three features, not all of them.[3]
Androgen excess, either visible on your skin and hair or measurable in your blood. Ovulation that has become irregular or stopped. Ovaries that look polycystic on ultrasound.
Pick any two and you qualify. That gives four combinations, and researchers label them A through D.[4]
Those four combinations do not behave the same way. Insulin resistance runs through roughly 80% of women with the two hyperandrogenic and anovulatory forms, around 65% of the ovulatory hyperandrogenic form, and about 38% of the form without androgen excess.[4]
Half your metabolic risk depends on which two of the three criteria you happened to meet. A clinician who does not know your phenotype cannot know which risks apply to you.
Work out yours below.
Which Phenotype
Tap whichever apply to you. Orientation for an appointment, not a diagnosis, and the ultrasound question needs an ultrasound.
One detail from the literature deserves your attention here, because it explains part of why your GP may not recognise you.
Across a meta-analysis of 41 studies, the classic form made up roughly half of the women seen in specialist clinics and under a fifth of women found in unselected populations.[4] The picture in a clinician's head comes from clinic patients. If your presentation sits closer to the milder end, you look less like the textbook to them and more like nothing much at all.
The engine underneath
Now the mechanism, because everything practical follows from it.
Researchers measured insulin resistance in PMOS using euglycaemic-hyperinsulinaemic clamp studies, which is the reference method rather than a blood test estimate. Their meta-analysis found insulin resistance present in women with the condition regardless of weight, including women who are lean.[5]
Read that twice if you have ever been told your weight is the problem, or told you cannot have this because you are slim.
Raised insulin then does two things at once. It pushes the theca cells of your ovaries to make more androgen. It also tells your liver to make less sex hormone binding globulin, the protein that keeps testosterone bound and inactive.[4]
Two taps, one basin. Production goes up while the brake comes off.
And the androgens then act on your fat tissue in a way that worsens insulin sensitivity, which raises insulin, which starts the whole thing again.[4] Researchers call it a vicious cycle in the literature, and for once the phrase earns itself.
Tap any step to see what intervenes there.
The Loop, and Where to Break It
Six steps that feed each other. Every treatment offered for PMOS enters this loop somewhere, and knowing where tells you what it will and will not fix.
Why "lose weight" fails so many women
Return to that survey for a moment. When those 1385 women were asked what concerned them most about their condition, the top answer was difficulty losing weight, at 53.6%. Irregular cycles came second, infertility third.[1]
Their single biggest concern was the thing they were being prescribed as a solution.
Weight loss does improve symptoms in women with PMOS who carry extra weight, and I want it stated rather than buried.[3] The failure sits in the sequencing.
Look at the loop again. Excess androgen alters where your body stores fat and lowers insulin sensitivity in muscle. So a woman with the hyperandrogenic form is being asked to change her body composition while the condition itself works against her doing so, and while nobody has treated the signal driving it.
Address the insulin picture first and the same effort starts producing different results. Skip it, hand her a diet sheet, and she will come back in a year having failed at something that was arranged to be difficult. Then she will believe the failure belongs to her, because nobody explained the arrangement.
The four numbers that carry the information
Four numbers carry most of the information, and clinicians order them inconsistently.[4]
Free testosterone, and SHBG beside it
Total testosterone on its own can look unremarkable while your free testosterone runs high, because low SHBG has released what was bound. Ask for both, and for the free androgen index that comes from them. Of the androgen measures, free testosterone tracks metabolic risk most closely.[4]
The LH to FSH ratio
In the classic form, luteinising hormone runs high relative to FSH. That ratio reflects a change in how your hypothalamus pulses its signals, and the raised LH drives theca cell androgen production while disrupting follicle maturation. Either hormone alone tells you less than the two together.[4]
HOMA-IR
Calculated from fasting glucose and fasting insulin. Fasting glucose by itself moves late, so a normal glucose result with no insulin measured alongside it leaves the metabolic question open rather than answered.[4]
AMH
The 2023 international guideline accepts anti-Müllerian hormone as an alternative to ultrasound for the ovarian morphology criterion in adults.[3] A blood test can now stand in for the scan, which matters if you are young, or waiting, or would rather not have a transvaginal ultrasound to confirm something a vial of blood can answer.
What is emerging, and how far I would trust it
Two areas come up in PMOS content with more confidence than the evidence carries.
The first is inflammation. Researchers keep finding raised inflammatory and adipokine markers in women with PMOS, and this work is moving toward risk stratification rather than diagnosis.[4] The relationship with androgens and insulin appears to run in both directions. What nobody can yet tell you is whether treating the inflammation changes your outcome, because the trials have not been done.
The second is the gut microbiome. Women with PMOS show a different microbial composition from matched controls, and one proposed route runs from gut-derived bacterial products into circulation, into inflammatory signalling, into insulin resistance. That chain is plausible, it connects to work I have written about before, and it remains correlational. Nobody has demonstrated that changing your microbiome changes your androgens.
I include both because you will meet them elsewhere stated with far more confidence than the evidence carries. A high fibre, plant-diverse diet is worth eating on its own merits. Buy it as a microbiome cure for PMOS and you have bought something nobody has proven.
The part of you nobody screens
Depression and anxiety occur at higher rates in women with PMOS than in women without it, and the 2023 international guideline recommends screening all adults and adolescents with the condition for both.[3]
Ask yourself whether anyone has ever screened you.
The recommendation exists in the guideline. It arrives in the consultation rarely. And the psychological load here is not only the reasonable distress of living with a chronic condition, though that alone would justify the screening. Neuroendocrine dysregulation runs through the condition itself, and the emotional consequences may connect to it directly.
Where each treatment enters the loop
Every option enters that loop somewhere. Knowing the entry point tells you what to expect.
The combined pill suppresses LH and raises SHBG, which lowers free testosterone and regulates bleeding. It manages what you can see while the insulin picture underneath continues unaddressed. Useful, and not the same as treatment.
Anti-androgens block the receptor. They work on skin and hair, and they leave the metabolic driver where it was.
Metformin enters upstream, improving insulin sensitivity and lowering hepatic glucose output. The 2023 guideline positions it for metabolic features alongside lifestyle.[3]
Inositol acts on insulin signalling and carries a favourable side effect profile. The 2023 guideline treats it as having uncertain benefit and considers it may be used, which sits well below the evidence behind metformin.[3] I say that as someone who finds the mechanism interesting.
Resistance training raises glucose disposal in skeletal muscle, which is where most circulating glucose ends up. It acts on the same upstream step metformin does, through a different door.
Notice the pattern. The two treatments women are offered first, the pill and weight loss advice, sit at the downstream end and the hardest end respectively. The upstream options exist and get raised less often.
The Appointment Deck
Eight cards. Tap any to see why it matters and the sentence to say. Ten minutes goes fast, so take the two or three that fit you.
Why this took so long
The name did some of this damage. A condition called polycystic ovary syndrome routes to gynaecology, gets managed reproductively, and hides its metabolic core behind a word describing follicles that are not cysts and are not always there. The consensus authors said as much when they replaced it, listing delayed diagnosis, fragmented care and stigma among the consequences.[2]
The rest belongs to a familiar pattern. Women reporting a cluster of symptoms across decades. A mechanism sitting in the literature since long before it reached consultations. And a standard response, the pill plus a suggestion about weight, that addresses the visible end of the loop while the engine keeps running.
One in eight women lives with this.[2] The mechanism is not obscure. The guideline recommending psychological screening and metabolic workup was published in 2023.[3] The distance between what the guideline says and what happens in the room is where you are standing.
A researcher writing to The Lancet after the rename made the point I keep returning to. The new name should be judged by whether it changes clinical behaviour and what patients experience, rather than by how many people adopt the word.
That puts the work somewhere less satisfying than a headline. It sits in individual appointments, one woman at a time, asking for the fasting insulin and the SHBG and the psychological screening the guideline already says she should have been offered.
You should not have to do that. Do it anyway, and take the specific words with you.
For the women reading
Take the phenotype with you. Which two of the three criteria you meet changes your metabolic risk, changes which investigations apply, and changes what the treatments will do for you. A consultation that never establishes it cannot give you a plan that fits.
If you have been told your weight is the problem, remember that clamp studies find insulin resistance in women with this condition across the weight range, lean women included. Weight is one output of the loop. Sequencing matters, and the insulin picture comes first.
None of this is medical advice, and no article knows your history. Bring the specific requests, and treat the 2023 guideline as something you are entitled to rather than something to hope for.
References
- Gibson-Helm, M., Teede, H., Dunaif, A., & Dokras, A. (2017). Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 102(2), 604–612. https://doi.org/10.1210/jc.2016-2963
- Teede, H. J., Bahri Khomami, M., Morman, R., et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, 407, 2329–2339. https://doi.org/10.1016/S0140-6736(26)00717-8
- Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
- Ma, Y.-C., Law, K.-S., Wang, W.-S., & Chang, H.-M. (2025). Phenotypic variations in polycystic ovary syndrome: metabolic risks and emerging biomarkers. Journal of Endocrinology, 267(1), e250226. https://doi.org/10.1530/JOE-25-0226
- Cassar, S., Misso, M. L., Hopkins, W. G., Shaw, C. S., Teede, H. J., & Stepto, N. K. (2016). Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Human Reproduction, 31(11), 2619–2631. https://doi.org/10.1093/humrep/dew243